These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23440683)

  • 1. Gaussian mixture model-based classification of dynamic contrast enhanced MRI data for identifying diverse tumor microenvironments: preliminary results.
    Han SH; Ackerstaff E; Stoyanova R; Carlin S; Huang W; Koutcher JA; Kim JK; Cho G; Jang G; Cho H
    NMR Biomed; 2013 May; 26(5):519-32. PubMed ID: 23440683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.
    Cho H; Ackerstaff E; Carlin S; Lupu ME; Wang Y; Rizwan A; O'Donoghue J; Ling CC; Humm JL; Zanzonico PB; Koutcher JA
    Neoplasia; 2009 Mar; 11(3):247-59, 2p following 259. PubMed ID: 19242606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
    Muñoz NM; Minhaj AA; Maldonado KL; Kingsley CV; Cortes AC; Taghavi H; Polak U; Mitchell JM; Ensor JE; Bankson JA; Rashid A; Avritscher R
    Magn Reson Imaging; 2019 Apr; 57():156-164. PubMed ID: 30465870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiosensitizing oxygenation changes in murine tumors treated with VEGF-ablation therapy are measurable using oxygen enhanced-MRI (OE-MRI).
    Baker JHE; Moosvi F; Kyle AH; Püspöky Banáth J; Saatchi K; Häfeli UO; Reinsberg SA; Minchinton AI
    Radiother Oncol; 2023 Oct; 187():109795. PubMed ID: 37414252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semi-automatic segmentation from intrinsically-registered 18F-FDG-PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE-MRI.
    Andreassen MMS; Goa PE; Sjøbakk TE; Hedayati R; Eikesdal HP; Deng C; Østlie A; Lundgren S; Bathen TF; Jerome NP
    MAGMA; 2020 Apr; 33(2):317-328. PubMed ID: 31562584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data-driven mapping of hypoxia-related tumor heterogeneity using DCE-MRI and OE-MRI.
    Featherstone AK; O'Connor JPB; Little RA; Watson Y; Cheung S; Babur M; Williams KJ; Matthews JC; Parker GJM
    Magn Reson Med; 2018 Apr; 79(4):2236-2245. PubMed ID: 28856728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.
    Sun X; Ackerstaff E; He F; Xing L; Hsiao HT; Koutcher JA; Ling CC; Li GC
    Oncotarget; 2015 Oct; 6(33):34732-44. PubMed ID: 26416246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts.
    Ovrebø KM; Ellingsen C; Galappathi K; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e121-7. PubMed ID: 22381901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delineation of Tumor Habitats based on Dynamic Contrast Enhanced MRI.
    Chang YC; Ackerstaff E; Tschudi Y; Jimenez B; Foltz W; Fisher C; Lilge L; Cho H; Carlin S; Gillies RJ; Balagurunathan Y; Yechieli RL; Subhawong T; Turkbey B; Pollack A; Stoyanova R
    Sci Rep; 2017 Aug; 7(1):9746. PubMed ID: 28851989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal approach to assess tumour vasculature and potential treatment effect with DCE-US and DCE-MRI quantification in CWR22 prostate tumour xenografts.
    Arteaga-Marrero N; Rygh CB; Mainou-Gomez JF; Nylund K; Roehrich D; Heggdal J; Matulaniec P; Gilja OH; Reed RK; Svensson L; Lutay N; Olsen DR
    Contrast Media Mol Imaging; 2015; 10(6):428-37. PubMed ID: 26010530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice.
    Feng Y; Jeong EK; Mohs AM; Emerson L; Lu ZR
    Magn Reson Med; 2008 Dec; 60(6):1347-52. PubMed ID: 19025902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content.
    Farace P; Merigo F; Fiorini S; Nicolato E; Tambalo S; Daducci A; Degrassi A; Sbarbati A; Rubello D; Marzola P
    Eur J Radiol; 2011 Apr; 78(1):52-9. PubMed ID: 19443159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying in vivo DCE MRI markers associated with microvessel architecture and gleason grades of prostate cancer.
    Singanamalli A; Rusu M; Sparks RE; Shih NN; Ziober A; Wang LP; Tomaszewski J; Rosen M; Feldman M; Madabhushi A
    J Magn Reson Imaging; 2016 Jan; 43(1):149-58. PubMed ID: 26110513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of fraction of hypoxic cells in human tumor xenografts with necrotic regions by dynamic contrast-enhanced MRI.
    Egeland TA; Gaustad JV; Benjaminsen IC; Hedalen K; Mathiesen B; Rofstad EK
    Radiat Res; 2008 Jun; 169(6):689-99. PubMed ID: 18494552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactate MRSI and DCE MRI as surrogate markers of prostate tumor aggressiveness.
    Yaligar J; Thakur SB; Bokacheva L; Carlin S; Thaler HT; Rizwan A; Lupu ME; Wang Y; Matei CC; Zakian KL; Koutcher JA
    NMR Biomed; 2012 Jan; 25(1):113-122. PubMed ID: 21618306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.
    Røe K; Mikalsen LT; van der Kogel AJ; Bussink J; Lyng H; Ree AH; Marignol L; Olsen DR
    Radiat Oncol; 2012 May; 7():75. PubMed ID: 22621752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced MRI of nasopharyngeal carcinoma: correlation of quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters with hypoxia-inducible factor 1α expression and tumor grade/stage.
    Liu L; Hu L; Zeng Q; Peng D; Chen Z; Huang C; Liu Z; Wen Q; Zou F; Yan L
    Ann Palliat Med; 2021 Feb; 10(2):2238-2253. PubMed ID: 33725777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-individual comparison of different gadolinium-based contrast agents in the quantitative evaluation of C6 glioma with dynamic contrast-enhanced magnetic resonance imaging.
    Li Y; Liu G; Lou X; Chen Z; Ma L
    Sci China Life Sci; 2017 Jan; 60(1):11-15. PubMed ID: 28078511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation of prostate cancer from normal prostate tissue in an animal model: conventional MRI and dynamic contrast-enhanced MRI.
    Gemeinhardt O; Lüdemann L; Prochnow D; Abramjuk C; Taupitz M; Hamm B; Beyersdorff D
    Rofo; 2005 Jul; 177(7):935-9. PubMed ID: 15973594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model.
    Ceelen W; Smeets P; Backes W; Van Damme N; Boterberg T; Demetter P; Bouckenooghe I; De Visschere M; Peeters M; Pattyn P
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1188-96. PubMed ID: 16457965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.